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OBJECTIVES We sought to test the hypothesis that patients with decompensated heart failure (HF) lose a
compensatory process whereby nitric oxide (NO) maintains pulmonary vascular tone.
BACKGROUND Exhaled nitric oxide (eNO) partially reflects vascular endothelial NO release. Levels of eNO
are elevated in patients with compensated HF and correlate inversely with pulmonary artery
pressures (PAP), reflecting pulmonary vasodilatory activity.
METHODS We measured the mean mixed expired NO content of a vital-capacity breath using
chemiluminescence in patients with compensated HF (n  30), decompensated HF (n  7)
and in normal control subjects (n  90). Pulmonary artery pressures were also measured in
patients with HF. The eNO and PAP were determined sequentially during therapy with
intravenous vasodilators in patients with decompensated HF (n  7) and in an additional
group of patients with HF (n  13) before and during administration of milrinone.
RESULTS The eNO was higher in patients with HF than in control subjects (9.9  1.1 ppb vs. 6.2 
0.4 ppb, p 0.002) and inversely correlated with PAP (r0.81, p 0.00001). In marked
contrast, patients with decompensated HF exhibited even higher levels of eNO (20.4  6.2
ppb) and PAP, but there was a loss of the inverse relationship between these two variables.
During therapy (7.3  6 days) with sodium nitroprusside and diuresis, hemodynamics
improved, eNO concentrations fell (11.2  1.2 ppb vs. before treatment, p  0.05), and the
relationship between eNO and PAP was restored. After milrinone, eNO rose proportionally
with decreased PAP (p  0.05).
CONCLUSIONS Elevated eNO may reflect a compensatory circulatory mechanism in HF that is lost in
patients with clinically decompensated HF. The eNO may be an easily obtainable and
quantifiable measure of the response to therapy in advanced HF. (J Am Coll Cardiol 2002;
40:1114–9) © 2002 by the American College of Cardiology Foundation
The circulation in congestive heart failure (HF) is charac-
terized by increases in both systemic and pulmonary vascular
tone (1), changes mediated by humoral and neurogenic
signals that include the renin-angiotensin-aldosterone sys-
tem, the sympathetic nervous system, and endothelin (2). A
primary counter-regulatory mechanism mediating vascular
relaxation is endothelial release of nitric oxide (NO) (3–5).
Both agonist-induced and baseline NO production have
been studied in HF. Whereas agonist-stimulated vascular
NO release is impaired, as indicated by diminished
acetylcholine-mediated vasodilatory responses, baseline NO
release may be elevated in HF (6–9). In this regard, the
vasoconstrictive response to NG-monomethyl-L-arginine
(L-NMMA), an inhibitor of NO synthesis, is exaggerated in
patients with HF (10), and plasma nitrate, a stable end product
of NO production, is increased in patients with HF (11).
Nitric oxide measured in exhaled air (eNO) reflects
production by both the airway and vascular endothelial cells
(12). Patients with HF demonstrate inverse correlations
between eNO and pulmonary vascular resistance (PVR) and
systemic vascular resistance (SVR), consistent with biolog-
ical activity of NO to produce vasodilation (13). Other
findings support this relationship between eNO and NO
release by the vasculature. For example, levels of eNO rise
with administration of both the NO synthase precursor
L-arginine and nitrates (14–16), and exercise enhances
eNO, likely due to vasodilatory endothelial release (17,18).
As the neurohormonal factors that contribute to the
transition from “compensated” to “decompensated” HF are
not fully explained, we sought to test whether patients with
advanced HF would demonstrate a loss of the relationship
between pulmonary artery pressure (PAP), which rises with
advancing HF, and eNO, suggesting an impairment of
compensatory NO production in HF. Moreover, we tested
whether treatment of HF would restore the relationship
between PAP and eNO, suggesting a restoration of a
compensatory process and the possibility that eNO could be
used as a clinical marker of HF severity and responsiveness
to treatment.
METHODS
Subjects. A historic control group from a previous study by
Massaro et al. (19) consisted of 58 women and 32 men
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(average age 30.9 years [range 19 to 65 years]) with no
history of heart problems (19). The compensated HF group
consisted of inpatients and outpatients (n  30) being
managed for HF. These patients underwent diagnostic
right-heart catheterization on the day of eNO measurement
to obtain right- and left-sided filling pressures, PAP, and
cardiac output. A confirmatory case-control study was
conducted in patients with HF (n 5; mean age 37.2 years)
matched with control subjects (n  5; mean age 39.4 years)
who were family members exposed to similar environmental
conditions. The patients with decompensated HF (n  7)
comprised patients admitted to the Cardiac Critical Care
Unit to undergo therapy with intravenous agents during
invasive cardiac monitoring with a pulmonary artery cathe-
ter. These patients were prospectively selected based on
signs and symptoms of profound volume overload or low
cardiac output (20). All subjects gave written, informed
consent for participation in the protocol, as approved by the
Committee for the Protection of Human Subjects From
Research Risks at Brigham and Women’s Hospital, Boston.
Determination of eNO levels. Levels of NO were mea-
sured in mixed expired air from all subjects, as previously
described by Massaro et al. (19). The method of NO
measurements in both historic control groups and the group
with compensated HF were identical. Five patients with HF
and their matched control subjects underwent NO measure-
ments after performing deep breathing for 1 min through
a one-way valve from a Douglas bag filled with NO-free air
(0.5 ppb).
Tailored HF therapy protocol. Patients with decompen-
sated HF in the critical care setting were placed on tailored
therapy for HF (21). Baseline hemodynamic variables were
measured as described by Stevenson et al. (20). Intravenous
sodium nitroprusside (SNP) and diuretics were adminis-
tered in dosages tailored to achieve an optimal SVR1,200
dynes-s per cm5 and systolic blood pressure 80 mm Hg
within 24 to 48 h. Once SVR was optimized, patients were
weaned off SNP and started on captopril. Serial measure-
ments of eNO were determined using the protocol de-
scribed by Massaro et al. (19).
Milrinone therapy protocol. Thirteen additional patients
with HF were treated with milrinone. Each underwent
right-heart catheterization and received milrinone by a
bolus injection of 50 g/kg over 1 min (22). Hemodynamic
variables and eNO were measured at baseline and after 20
min by the methods described earlier.
Statistical analysis. Data are expressed as the mean value
 SEM in the patient study group and as the mean value
SD in the matched control group. The unpaired two-tailed
Student t test was used to analyze the differences in eNO
levels between the historic control group and HF group.
Comparisons between patients with HF and their matched
control subjects were calculated using the paired two-tailed
Student t test. Analysis of patients with HF at baseline,
during SNP treatment, and after therapy were performed
with analysis of variance. Post-hoc analysis was performed
using the Student-Newman-Keuls test. The relationship
between eNO and PAP was tested using linear regression.
Multiple linear regression was used to test for the indepen-
dent impact of age, gender, forced expiratory volume in 1 s
(FEV1), FEV1/forced vital capacity (FVC) ratio, and con-
comitant use of nitrates on the relationship between eNO
and PAP. A level of p  0.05 was accepted as statistically
significant.
RESULTS
Study group. The baseline characteristics of the study
patients are shown in Table 1. The eNO was significantly
elevated in the compensated HF group compared with the
control group (9.9 1.1 ppb vs. 6.2 0.4 ppb, p 0.0002)
(Fig. 1), and PAP inversely correlated with eNO (r 
0.81, p 0.00001) (Fig. 2). Exhaled NO did not correlate
with New York Heart Association (NYHA) functional
Abbreviations and Acronyms
cGMP  cyclic guanosine 3,5-monophosphate
eNO  exhaled nitric oxide
FEV1  forced expiratory volume in 1 s
FVC  forced vital capacity
HF  heart failure
L-NMMA  NG-monomethyl-L-arginine
NO  nitric oxide
NYHA  New York Heart Association
PAP  pulmonary artery pressure
PVR  pulmonary vascular resistance
SNP  sodium nitroprusside
SVR  systemic vascular resistance
Table 1. Baseline Characteristics of Study Group
Patients With
Compensated HF
(n  30)
Patients With
Decompensated HF
(n  7)
Age (yrs) 53  1 51  4
Male gender (%) 64 86
NYHA functional class (%)
I–II 20 0
III–IV 80 100
CHF etiology (%)
Cardiomyopathy 55 29
CAD 20 57
Other 25 14
RAP (mm Hg) 11.1  1.2 16.6  2.8*
PAP, systolic (mm Hg) 42.2  2.8 61.4  3.3*
PAM (mm Hg) 30.0  2.2 43.5  2.5*
PCWP (mm Hg) 20.6  2.0 31.0  3.0*
PVR (dynes-s per cm5) 252  49 356  47
CO (l/min) 4.2  0.4 3.0  0.3*
FEV1/FVC ratio 0.82  0.02 0.83  0.03
*p  0.05 vs. compensated HF group. Data are presented as the mean value  SEM
or percentage of patients.
CAD  coronary artery disease; CHF  congestive heart failure; CO  cardiac
output; FEV1/FVC  forced expiratory volume in 1 s to forced vital capacity ratio;
HF  heart failure; NYHA  New York Heart Association; PAM  mean
pulmonary aterial pressure; PAP  pulmonary artery pressure; PCWP  pulmonary
capillary wedge pressure; PVR  pulmonary vascular resistance; RAP  right atrial
pressure.
1115JACC Vol. 40, No. 6, 2002 Hare et al.
September 18, 2002:1114–9 Exhaled NO in HF
class. In a multiple linear regression analysis, PAP remained
independently associated with eNO after adjustment for
age, gender, FEV1, FEV1/FVC ratio, and concomitant use
of nitrates.
Matched control study. The aforementioned results were
confirmed in a small case-control study in which all patients
with HF exhibited higher levels of eNO, as compared with
their matched control subjects (8.4  3.5 ppb vs. 6.5  2.4
ppb, p  0.04).
eNO in patients with decompensated HF. Despite
higher systolic PAP, patients with decompensated HF
(Table 1) did not have low eNO levels. In contrast, the
highest eNO levels were observed among these patients. In
addition, there was no correlation between eNO and PAP
in these patients (Fig. 2). Moreover, combining the systolic
PAP and eNO data from the patients with decompensated
and compensated HF eliminated the linear relationship
between these variables (r  0.01, p  0.95).
To assess whether treatment that improved hemodynam-
ics in HF restored the relationship between eNO and PAP,
we serially monitored eNO concentrations during hemody-
namically guided vasodilator therapy in these patients. The
eNO progressively decreased during SNP therapy (11.2 
1.2 ppb vs. 20.4  6.2 ppb at baseline, p  0.05) (Fig. 3).
This was accompanied by a reduction of PVR, improved
cardiac output, and decreased pulmonary capillary wedge
pressure (Table 2). Early administration of SNP did not
increase eNO values (Table 2).
Although baseline levels of eNO did not correlate with
PAS in this group, the relationship was restored after
therapy (Fig. 2). With inclusion of the post-treatment data
in the linear regression between eNO and PAP, this
relationship persisted (r  0.66, p  0.0001). The
baseline FEV1/FVC ratios in these patients with decom-
pensated HF did not change significantly after therapy (0.83
 0.03 vs. 0.77  0.07, p  0.43).
Response of eNO and PAP to milrinone. In 13 addi-
tional patients given milrinone to reduce PAP, there was a
significant inverse correlation between the change in eNO
and the change in PAP (r  0.61, p  0.027), such that
the greater the PAP reduction, the greater the increase in
eNO (Fig. 4). In patients in whom PAP did not change or
actually increased, eNO declined. In contrast to the rela-
tionship with PAP, eNO did not correlate with changes in
cardiac output in response to milrinone.
DISCUSSION
This study demonstrates that patients with advanced de-
compensated HF have profoundly elevated baseline eNO
levels, in contrast to patients with all other degrees of HF
(NYHA functional classes I to IV). In contrast to patients
with compensated HF who exhibit a correlation between
PAP and eNO, patients with decompensated HF do not.
However, with treatment that restores hemodynamics, eNO
levels fall, and the relationship between eNO and PAP is
restored. Thus, measurement of eNO may be useful as an
indicator of progressive HF and has the potential to predict
the response to treatment.
Several groups have previously investigated levels of eNO
in HF. Funakoshi et al. (18) showed eNO to be elevated in
HF. Three other studies, however, demonstrated that eNO
was either decreased or unchanged in patients with HF
(13,23,24). Our findings demonstrate that patients with HF
have wide ranges of eNO, possibly explaining the discrep-
ancy in previous studies. Our results are consistent with
other assessments of NO production or bioactivity in HF.
Figure 1. Comparison of baseline exhaled nitric oxide (NO) in patients
with heart failure versus normal control subjects. The baseline exhaled NO
was significantly increased in the heart failure group. *p  0.0002.
Figure 2. Scatterplot demonstrating the correlation (r   0.81, p 
0.00001) between levels of exhaled nitric oxide (NO) and systolic pulmo-
nary artery pressure (PAP) in patients with compensated heart failure
(open circles). Linear regression lines with 95% confidence intervals are
depicted for patients with compensated heart failure. Patients with decom-
pensated heart failure at baseline (solid squares) deviated from this curve,
did not exhibit an inverse correlation between eNO and PAP, and
eliminated the linear relationship between PAP and eNO. The relationship
between these two variables was restored toward normal after tailored
therapy (solid inverted triangles). With inclusion of the post-treatment
data, the linear regression between NO and PAP persisted (r0.66, p
0.00005).
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Winlaw et al. (11) found plasma nitrates to be increased in
patients with HF compared with normal subjects. The
increased vasoconstrictive response to L-NMMA in patients
with HF also supports our conclusion that baseline produc-
tion of NO is enhanced in HF (10). Finally, Cooper et al.
(5) demonstrated that NO activity was diminished in
patients with HF and an elevated PVR index, but was
preserved in those with a normal PVR index, a finding that
correlates with our hypothesis that NO activity plays a
compensatory role in maintaining pulmonary vascular tone.
Loss of the inverse relationship between eNO and PAP
among patients with decompensated HF. Although base-
line eNO was higher in the HF group compared with the
control group, within the HF group, eNO levels inversely
correlated with PAP. This finding supports the compensa-
tory role of endothelial NO release in reducing PAP in
compensated HF, suggesting that eNO reflects bioactive
endothelial NO release capable of producing vascular relax-
ation. In contrast, patients with decompensated HF devi-
ated from this linear relationship and demonstrated a
marked elevation of both eNO and systolic PAP. This
finding likely reflects a loss of biological efficacy of NO in
these subjects. Treatment of these patients with decompen-
sated HF restored the inverse relationship between eNO
and PAP, consistent with a return to the compensated state.
We also observed an inverse correlation between the
Figure 3. Individual nitric oxide (NO) curves among patients with heart failure (n  7) in response to tailored therapy showing a progressive decline in
exhaled NO concentrations during heart failure treatment.
Table 2. Response of Exhaled Nitric Oxide and Hemodynamic
Variables to Heart Failure Therapy
Before
Therapy
SNP for
2 h
After
Therapy
NO (ppb) 20.4  6.2 22.8  4.6 11.2  1.2*
PVR (dynes-s per cm5) 356  47 287  63 147  32*
CO (l/min) 3  0.3 4.64  0.9 4.8  0.3†
PCWP (mm Hg) 31  3 27  2 21  7†
*p  0.05 vs. baseline and SNP and †p  0.05 vs. baseline (analysis of variance with
the Student-Newman-Keuls post-hoc test). Data are expressed as the mean value 
SEM.
NO  nitric oxide; SNP  sodium nitroprusside; other abbreviations as in Table 1.
Figure 4. Scatterplot demonstrating the inverse correlation between the
change in pulmonary artery pressure (PAP) and exhaled nitric oxide (eNO)
in response to acute administration of milrinone (r  0.61, p  0.027).
A decrease in PAP caused by milrinone was associated with a rise in eNO,
consistent with the inverse relationship depicted in Figure 1. In patients in
whom PAP remained unchanged or rose slightly with milrinone, eNO
actually fell, consistent with the notion that these patients have a defect in
nitric oxide pathway activity.
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change in PAP and eNO after early administration of
milrinone, a pulmonary vasodilator. This finding reinforces
our conclusion that eNO levels may reflect vascular reactiv-
ity. This finding is relevant because milrinone is not a precursor
in the NO pathway. Furthermore, it is also unlikely that a
change in cardiac output affected the change in eNO, because
there was no correlation between these variables.
Our findings demonstrate that NO production is intact
and possibly elevated in patients with decompensated HF.
The concurrent loss of the inverse correlation with PAP
suggests compromised NO activity. Cyclic guanosine 3,5-
monophosphate (cGMP), the second messenger mediating
vascular smooth muscle relaxation, is also elevated in the
plasma of patients with HF (25–28). These findings suggest
that a defect in the NO pathway may occur downstream of
cGMP signaling. Although confounding factors such as
airway inflammation and bronchospasm secondary to pul-
monary edema may also cause eNO to rise and subsequently
fall with treatment, this explanation is less likely, because
baseline FEV1/FVC ratios in patients with decompensated
HF did not exhibit obstructive patterns and did not change
significantly after therapy (29).
eNO as a marker of endothelial function. This study
supports the relationship between eNO and endothelial NO
production. Other evidence for this association comes from
observations that eNO rises with administration of NO
precursors and with exercise. However, a recent study
involving healthy subjects has shown that although
L-NMMA infusion elicits appropriate hemodynamic
changes, it does not concomitantly affect eNO (30). Fur-
thermore, Dirnberger et al. (31) observed that intravenous
infusion of nitrates does not increase eNO among healthy
subjects. A recent study has also suggested that exercise-
induced increases in eNO more likely result from increased
expiratory air flow rates than from endogenous NO produc-
tion (32). However, these studies were performed in healthy
subjects, and their results may not take into account the
intrinsic differences in NO production in HF. The inverse
correlation between levels of eNO and PAP supports the
idea that eNO reflects endothelial release. This finding is in
agreement with the data of Sumino et al. (13), who found a
similar relationship between the rate of NO release and
peripheral vascular resistance. The decrease in eNO associ-
ated with the clinical response to HF therapy, as measured
by established hemodynamic parameters provides additional
evidence that NO produced in the lower airways is a marker
of vascular endothelial function. However, the response of
NO to hemodynamic improvement may also reflect a
decrease in bronchial hyper-responsiveness caused by pul-
monary vascular congestion. Our data further imply that the
loss of the relationship between eNO and PAP is a
reflection of a loss of vascular reactivity due to either
diminished activity of NO or augmented activity of other
neurohumoral factors.
Study limitations. The use of historic data in this study
raises the concern of confounding factors. A multiple linear
regression analysis, however, did not show an influence of
age, gender, and use of nitrates on eNO levels. We also
confirmed our findings in a subsequent matched control
study. Furthermore, our study did not address whether
other neurohumoral factors, such as angiotensin II,
endothelin-1, norepinephrine, and brain natriuretic peptide,
contributed to elevated PAP in patients with decompen-
sated HF and thus the loss of the inverse relationship
between eNO and PAP. The number of patients with
decompensated HF may also have been too small to detect
either a negative or positive correlation between eNO and
PAP in this population.
Clinical implications. Despite advances in HF treatment,
reliable noninvasive markers of therapy are only recently
becoming available. Most end points for treatment are based
on the clinical symptoms of the patient, and this approach
may fall short of adequate therapy that is needed to optimize
hemodynamics. Traditionally, invasive monitoring (with
Swan-Ganz catheters) has been used to guide therapy.
However, invasive monitoring is not without risk or ex-
pense, and other markers of successful treatment are needed.
Biological markers such as brain natriuretic peptide will play
an important role in monitoring and tailoring HF therapy in
the future (33).
Although the correlation between eNO levels and clinical
improvement has been demonstrated in noncardiac condi-
tions such as asthma, our study is the first to report the use
of measured eNO as an indicator of decompensation in HF
and as a marker of the response to treatment (19,29). This
biological marker is particularly useful in selecting patients
for inpatient HF therapy. A patient in the compensated
state would typically be represented on the linear curve that
reflects the inverse correlation between NO and PAP. Serial
NO measurements may be able to detect when a patient
deviates from this curve and may predict progression to
decompensated HF. Furthermore, a decrease in eNO after
therapy correlates with hemodynamic improvement, provid-
ing a noninvasive marker of therapeutic efficacy. Future
studies to refine the NO-PAS relationship and to define the
values associated with decompensation yield the potential
for developing a simple system to detect advanced HF and
therapeutic responsiveness.
Conclusions. The eNO is elevated in patients with com-
pensated HF, and there is an inverse correlation between
eNO and PAP. This relationship is lost in patients with
decompensated HF and is subsequently restored after he-
modynamic improvement with tailored therapy. Furthermore,
the response of eNO to a pulmonary artery vasodilator in-
versely correlates with the change in PAP. Our study provides
further evidence that eNO is a marker of endothelial function.
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